source
- Novo outlines plan for multiple new drugs to regain market share as shares dip 8%At a capital markets day in London, Novo executives presented a roadmap to launch more than five multi-blockbuster drugs by 2030 and target $23 billion in annual sales by 2035, aiming to offset the…
- Sleuth predicts surge in Western licensing of Chinese radioligand therapies by 2027Sleuth, a biopharma intelligence platform, says that while Chinese radiopharmaceutical assets have seen few licensing deals so far, the market is set to change. The firm notes that China now runs…